Therapy Areas: Hereditary Disorders
JHL Biotech to launch three-arm pharmacokinetic study in healthy volunteers in Bulgaria to treat colorectal, lung and ovarian cancers
23 February 2018 -

Biopharmaceutical startup JHL Biotech Inc reported on Thursday the receipt of approval from the European authority, Bulgarian Drug Agency for a Phase I Clinical Trial Application for a proposed bevacizumab biosimilar, JHL1149.

Following the approval, the company will launch a three-arm pharmacokinetic study in healthy volunteers in Bulgaria beginning March 2018.

The company said that the data from this trial will support the rapid development and commercialisation of JHL1149. JHL1149 would provide an affordable alternative to bevacizumab, a biologic used to treat many cancers, the most common of which are metastatic colorectal cancer, lung cancer and ovarian cancer.

Currently, the company expects several biosimilars to be in clinical trials: Rituximab biosimilar (JHL1101) to treat rheumatoid arthritis and Non-Hodgkin's Lymphoma; Dornase alfa biosimilar (JHL1922) to manage symptoms of cystic fibrosis; as well as Trastuzumab biosimilar (JHL1188) to treat breast cancer.

Login
Username:

Password:


Related Headlines

Vertex, Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies

Vertex to Submit Cystic Fibrosis Medicines Orkambi as Well as Symkevi to be Used in Combination with ivacaftor, to the Scottish Medicines Consortium for Appraisal

Non–Cystic Fibrosis Bronchiectasis FDA Grants "Fast-Track" and "QIPD" to Zambon for Colistimethate Sodium Powder for Nebulizer Solution Delivered by the I-neb AAD System

Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis

Vertex Receives European CHMP Positive Opinion for Orkambi (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common form of the Disease

Verona Pharma completes patient enrolment for phase two trial of RPL554

Vertex Pharmaceuticals (Europe) receives positive opinion from European watchdog for Kalydeco

Synspira Receives US FDA Orphan Designation for PAAG15A for the Treatment of Cystic Fibrosis

Decibel Therapeutics and Oricula Therapeutics Ink Exclusive License for ORC-13661 in Phase 1 Development for Hearing and Balance Protection

Synedgen Names Parker as Chief Business Officer

Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis, According to Gilead and Galapagos

Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis

Vertex, Genomics Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines

Vertex Receives a Positive PBAC Recommendation for Reimbursement of Orkambi to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation

ELITechGroup Biomedical Systems Launches Macroduct Advanced–A Sweat Induction and Collection Method Cleared by the FDA